Japan's stock market continued to climb for the third consecutive day, while other markets in the Asia-Pacific region experienced declines on Wednesday, Dec. 13.
Hong Kong
Hong Kong's Hang Seng Index (HSI) fell by 0.9% to 16,228.75.
The largest increase among the constituents of the Hang Seng Index was seen in shares of cell/mobile phones company Xiaomi, as they rose by 2.5%.
However, shares of glass/glass products company Xinyi Glass Holdings saw the largest drop in Hong Kong, weakening by 5.7% on Wednesday.
Similarly, shares of commercial/industrial real estate firm Wharf Real Estate Invt and marine transport company Orient Overseas Intl declined by 4.8% and 4.2%, respectively.
Japan
On the other hand, Japan's Nikkei 225 Index added 0.3% to reach 32,926.35.
The largest increase among the constituents of the Nikkei 225 Index was seen in shares of personal electronics company Sharp Corp., as they added 7.2%.
However, diversified holding companies company Kawasaki Heavy Industries saw the largest decrease on Wednesday, with shares dropping by 4.1%.
Shares of cinema film production firm Toho Co Ltd and computers/consumer electronics company Fujitsu fell by 3.7% each.
Other Markets
China's Shanghai Composite Index declined by 1.2% to reach 2,968.76.
Singapore stocks remained flat as The FTSE Straits Times Index stayed at 3,103.28.
The KOSPI Composite Index of South Korean stocks dropped by 1.0%, while the S&P/ASX 200 Benchmark Index of Australian stocks added 0.3%.
Among the noteworthy gainers in other markets were pharmaceuticals firm Hansoh Pharmaceutical and online service providers company Netease, rising by 2.1% and 1.7% respectively.
Similarly, shares of semiconductors firm Advantest Corp and semiconductors company Tokyo Electron gained 5.6% and 4.7% respectively.
Our Latest News
Bitcoin and Cryptocurrencies Experience Retreat amid Market Sell-Off
Bitcoin and other cryptocurrencies face a decline amidst a broader market sell-off. Analysts believe further decline is inevitable.
Positive Results for Phase 2 Study of Barzolvolimab in Chronic Spontaneous Urticaria
Celldex Therapeutics reports positive results for Phase 2 study of barzolvolimab in chronic spontaneous urticaria, a breakthrough treatment option for patients....
Unilever Reports Sales Growth and Margin Improvement
Unilever reports sales growth and margin improvement driven by turnaround plans, forecasting a positive outlook for 2024.